Valutazione dell'immunogenicità di un vaccino antinfluenzale a subunità combinato con l'emulsione adiuvante MF59 in un campione di anziani istituzionalizzati

Translated title of the contribution: Evaluation of immonogenity of a flu vaccine adjuvated with MF59 subunit combined emulsion ia a sample of elderly institutionalized patients

Fabrizio Pregliasco, A. Zanoni, F. Zaffanella, C. Gonella, M. Giacomazzi, M. Talassi, D. Tinazzi, G. Anselmi, C. Mensi, A. Giani, L. Fonte, S. Schieppati

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: In elderly people, because of complications, influenza can be a dangerous pathology. In elderly people common vaccination can be less immunogen because of reduction of immunity, and for this reason this study was conducted on an adjuvated vaccine (with MF59) (FLUAD Chiron, Siena) adjuvant), on a population of old people totally or partially non-self-sufficient, institutionalised, to show the immunogenicity of this vaccine. Results: The protection reached, after one month from vaccination, these data of immunizations: for people under 84 the 43,0% was protected for H1N1 and 43,7% for people over 85, protection for H3N2 was respectively 87,2% and 81,2%, finally for B virus protection was respectively 67,4% and 75,0%. Conclusions: These data show how this kind of vaccination could be used to obtain a better protection against influenza in elderly people than common vaccination that have a level of protection commonly under 30%. In the most old people (over 85 yrs) this adjuvated-vaccine is preferable than the non-adjuvated vaccine, also because of less important adverse reactions that are observed for this kind of vaccine in this target of people than in younger people.

Original languageItalian
Pages (from-to)41-45
Number of pages5
JournalGiornale di Gerontologia
Volume52
Issue number1
Publication statusPublished - Feb 2004

Fingerprint

Influenza Vaccines
Emulsions
Vaccination
Vaccines
Human Influenza
Cercopithecine Herpesvirus 1
Immunity
Immunization
Pathology
MF59 oil emulsion
Population

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Pregliasco, F., Zanoni, A., Zaffanella, F., Gonella, C., Giacomazzi, M., Talassi, M., ... Schieppati, S. (2004). Valutazione dell'immunogenicità di un vaccino antinfluenzale a subunità combinato con l'emulsione adiuvante MF59 in un campione di anziani istituzionalizzati. Giornale di Gerontologia, 52(1), 41-45.

Valutazione dell'immunogenicità di un vaccino antinfluenzale a subunità combinato con l'emulsione adiuvante MF59 in un campione di anziani istituzionalizzati. / Pregliasco, Fabrizio; Zanoni, A.; Zaffanella, F.; Gonella, C.; Giacomazzi, M.; Talassi, M.; Tinazzi, D.; Anselmi, G.; Mensi, C.; Giani, A.; Fonte, L.; Schieppati, S.

In: Giornale di Gerontologia, Vol. 52, No. 1, 02.2004, p. 41-45.

Research output: Contribution to journalArticle

Pregliasco, F, Zanoni, A, Zaffanella, F, Gonella, C, Giacomazzi, M, Talassi, M, Tinazzi, D, Anselmi, G, Mensi, C, Giani, A, Fonte, L & Schieppati, S 2004, 'Valutazione dell'immunogenicità di un vaccino antinfluenzale a subunità combinato con l'emulsione adiuvante MF59 in un campione di anziani istituzionalizzati', Giornale di Gerontologia, vol. 52, no. 1, pp. 41-45.
Pregliasco, Fabrizio ; Zanoni, A. ; Zaffanella, F. ; Gonella, C. ; Giacomazzi, M. ; Talassi, M. ; Tinazzi, D. ; Anselmi, G. ; Mensi, C. ; Giani, A. ; Fonte, L. ; Schieppati, S. / Valutazione dell'immunogenicità di un vaccino antinfluenzale a subunità combinato con l'emulsione adiuvante MF59 in un campione di anziani istituzionalizzati. In: Giornale di Gerontologia. 2004 ; Vol. 52, No. 1. pp. 41-45.
@article{5b3c0e22324b4bb5bc17bccea3974556,
title = "Valutazione dell'immunogenicit{\`a} di un vaccino antinfluenzale a subunit{\`a} combinato con l'emulsione adiuvante MF59 in un campione di anziani istituzionalizzati",
abstract = "Objective: In elderly people, because of complications, influenza can be a dangerous pathology. In elderly people common vaccination can be less immunogen because of reduction of immunity, and for this reason this study was conducted on an adjuvated vaccine (with MF59) (FLUAD Chiron, Siena) adjuvant), on a population of old people totally or partially non-self-sufficient, institutionalised, to show the immunogenicity of this vaccine. Results: The protection reached, after one month from vaccination, these data of immunizations: for people under 84 the 43,0{\%} was protected for H1N1 and 43,7{\%} for people over 85, protection for H3N2 was respectively 87,2{\%} and 81,2{\%}, finally for B virus protection was respectively 67,4{\%} and 75,0{\%}. Conclusions: These data show how this kind of vaccination could be used to obtain a better protection against influenza in elderly people than common vaccination that have a level of protection commonly under 30{\%}. In the most old people (over 85 yrs) this adjuvated-vaccine is preferable than the non-adjuvated vaccine, also because of less important adverse reactions that are observed for this kind of vaccine in this target of people than in younger people.",
keywords = "Adjuvant vaccine, Elderly immunization, Influenza vaccination, MF59",
author = "Fabrizio Pregliasco and A. Zanoni and F. Zaffanella and C. Gonella and M. Giacomazzi and M. Talassi and D. Tinazzi and G. Anselmi and C. Mensi and A. Giani and L. Fonte and S. Schieppati",
year = "2004",
month = "2",
language = "Italian",
volume = "52",
pages = "41--45",
journal = "Giornale di Gerontologia",
issn = "0017-0305",
publisher = "Pacini Editore s.r.l.",
number = "1",

}

TY - JOUR

T1 - Valutazione dell'immunogenicità di un vaccino antinfluenzale a subunità combinato con l'emulsione adiuvante MF59 in un campione di anziani istituzionalizzati

AU - Pregliasco, Fabrizio

AU - Zanoni, A.

AU - Zaffanella, F.

AU - Gonella, C.

AU - Giacomazzi, M.

AU - Talassi, M.

AU - Tinazzi, D.

AU - Anselmi, G.

AU - Mensi, C.

AU - Giani, A.

AU - Fonte, L.

AU - Schieppati, S.

PY - 2004/2

Y1 - 2004/2

N2 - Objective: In elderly people, because of complications, influenza can be a dangerous pathology. In elderly people common vaccination can be less immunogen because of reduction of immunity, and for this reason this study was conducted on an adjuvated vaccine (with MF59) (FLUAD Chiron, Siena) adjuvant), on a population of old people totally or partially non-self-sufficient, institutionalised, to show the immunogenicity of this vaccine. Results: The protection reached, after one month from vaccination, these data of immunizations: for people under 84 the 43,0% was protected for H1N1 and 43,7% for people over 85, protection for H3N2 was respectively 87,2% and 81,2%, finally for B virus protection was respectively 67,4% and 75,0%. Conclusions: These data show how this kind of vaccination could be used to obtain a better protection against influenza in elderly people than common vaccination that have a level of protection commonly under 30%. In the most old people (over 85 yrs) this adjuvated-vaccine is preferable than the non-adjuvated vaccine, also because of less important adverse reactions that are observed for this kind of vaccine in this target of people than in younger people.

AB - Objective: In elderly people, because of complications, influenza can be a dangerous pathology. In elderly people common vaccination can be less immunogen because of reduction of immunity, and for this reason this study was conducted on an adjuvated vaccine (with MF59) (FLUAD Chiron, Siena) adjuvant), on a population of old people totally or partially non-self-sufficient, institutionalised, to show the immunogenicity of this vaccine. Results: The protection reached, after one month from vaccination, these data of immunizations: for people under 84 the 43,0% was protected for H1N1 and 43,7% for people over 85, protection for H3N2 was respectively 87,2% and 81,2%, finally for B virus protection was respectively 67,4% and 75,0%. Conclusions: These data show how this kind of vaccination could be used to obtain a better protection against influenza in elderly people than common vaccination that have a level of protection commonly under 30%. In the most old people (over 85 yrs) this adjuvated-vaccine is preferable than the non-adjuvated vaccine, also because of less important adverse reactions that are observed for this kind of vaccine in this target of people than in younger people.

KW - Adjuvant vaccine

KW - Elderly immunization

KW - Influenza vaccination

KW - MF59

UR - http://www.scopus.com/inward/record.url?scp=3242774754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242774754&partnerID=8YFLogxK

M3 - Articolo

VL - 52

SP - 41

EP - 45

JO - Giornale di Gerontologia

JF - Giornale di Gerontologia

SN - 0017-0305

IS - 1

ER -